The decreasing trading performance of Zurich's General Insurance business has caused Zurich to terminate offer discussions with RSA. Zurich's due diligence findings on RSA met Zurich's expectations and did not contain any data that would have caused Zurich to withdraw their offer.
Showing posts with label withdraw. Show all posts
Showing posts with label withdraw. Show all posts
21 September 2015
Zurich/RSA Offer Comes to a Conclusion!
On July 28th 2015, Zurich, a global financial services company, openly considered purchasing the RSA Insurance Group. RSA owns Pets Plus Us, a new and unique pet insurance provider for pet owners in Canada.
The decreasing trading performance of Zurich's General Insurance business has caused Zurich to terminate offer discussions with RSA. Zurich's due diligence findings on RSA met Zurich's expectations and did not contain any data that would have caused Zurich to withdraw their offer.
The decreasing trading performance of Zurich's General Insurance business has caused Zurich to terminate offer discussions with RSA. Zurich's due diligence findings on RSA met Zurich's expectations and did not contain any data that would have caused Zurich to withdraw their offer.
21 April 2015
Paladin Labs (USA) Requests FDA Approval Withdrawal of Antizol-Vet
Paladin Labs (USA) has successfully requested that the U.S. Food and Drug Administration withdraw approval for Antizol-Vet (fomepizole, 4-methylpyrazole), an antidote for ethylene glycol poisoning in dogs. The approval withdrawal was announced on April 7th, 2015.
Paladin Labs requested the withdrawal as Antizol-Vet has not been produced or marketed since October 1st, 2014. The last lot of Antizol-Vet sold has an expiry date of August 2017.
Subscribe to:
Posts (Atom)